Literature DB >> 19137966

[Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers].

H F L Wertheim1, H S M Ammerlaan, M J M Bonten, P J van den Broek, A Troelstra, C M J E Vandenbroucke-Grauls, M C Vos, A Voss, J L Nouwen, J A J W Kluytmans.   

Abstract

The 'Stichting Werkgroep Antibioticabeleid' (SWAB; Dutch Working Party on Antibiotics Policy) has developed evidence-based guidelines for the antimicrobial treatment of methicillin-resistant Staphylococcus aureus (MRSA) carriers for the eradication of MRSA. A distinction was made between uncomplicated and complicated carriage depending on the presence or absence of an active MRSA infection, skin lesions, foreign body material, mupirocin resistance and/or extranasal carriage. The indication for treatment is determined by the consequences of carriage for the carrier and his/her environment, the adverse events of treatment, and the likelihood of a successful treatment. The first choice of treatment in uncomplicated carriers is a combination of mupirocin nasal ointment and disinfectant soap for 5 days, along with hygiene advice. If treatment fails, sources in the vicinity of the patient must be sought. Complicated carriers receive a combination of 2 oral antibiotics, in addition to mupirocin nasal ointment and disinfectant soap, for at least 7 days.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19137966

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  Good performance of the SpectraCellRA system for typing of methicillin-resistant Staphylococcus aureus isolates.

Authors:  R te Witt; N Vaessen; D C Melles; W S N Lekkerkerk; E A E van der Zwaan; W H A Zandijk; J A Severin; M C Vos
Journal:  J Clin Microbiol       Date:  2013-02-20       Impact factor: 5.948

2.  USA300, A strain of community-associated methicillin-resistant Staphylococcus aureus, crossing Belgium's borders: outbreak of skin and soft tissue infections in a hospital in Belgium.

Authors:  K Kaïret; E Ho; D Van Kerkhoven; J Boes; S Van Calenbergh; L Pattyn; P Lemay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-03       Impact factor: 3.267

3.  Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital.

Authors:  M M L van Rijen; J A J W Kluytmans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-07-18       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.